1. Home
  2. TRDA vs ALLT Comparison

TRDA vs ALLT Comparison

Compare TRDA & ALLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$10.29

Market Cap

386.8M

Sector

Health Care

ML Signal

HOLD

Logo Allot Ltd.

ALLT

Allot Ltd.

HOLD

Current Price

$9.80

Market Cap

429.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRDA
ALLT
Founded
2016
1996
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
386.8M
429.1M
IPO Year
2021
2006

Fundamental Metrics

Financial Performance
Metric
TRDA
ALLT
Price
$10.29
$9.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$20.00
$12.75
AVG Volume (30 Days)
167.3K
401.2K
Earning Date
11-06-2025
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.02
Revenue
$61,520,000.00
$98,512,000.00
Revenue This Year
N/A
$12.08
Revenue Next Year
$3.14
$12.38
P/E Ratio
N/A
$456.22
Revenue Growth
N/A
7.51
52 Week Low
$4.93
$4.37
52 Week High
$18.76
$11.42

Technical Indicators

Market Signals
Indicator
TRDA
ALLT
Relative Strength Index (RSI) 53.45 57.35
Support Level $9.89 $9.06
Resistance Level $11.55 $9.95
Average True Range (ATR) 0.51 0.40
MACD -0.21 0.05
Stochastic Oscillator 25.90 67.71

Price Performance

Historical Comparison
TRDA
ALLT

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About ALLT Allot Ltd.

Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.

Share on Social Networks: